Abbvie Discloses $216 Million In Q3 2026 R&D, Milestone Expenses
AbbVie Inc. reported that its Q3 2026 GAAP and adjusted earnings included $216 million in expenses for acquired intellectual property rights and milestones.
AbbVie Inc. reported that its Q3 2026 GAAP and adjusted earnings included $216 million in expenses for acquired intellectual property rights and milestones.